Searchable abstracts of presentations at key conferences in endocrinology

ea0028cmw2.2 | Controversies in aetiology and management of osteoporosis | SFEBES2012

Osteoporosis and metabolic bone disease in adolescence

Bishop Nick

The diagnosis of osteoporosis in the context of the growing skeleton requires both the presence of low bone mass for body size and a history of low trauma fractures. The presentation of osteoporosis may predate adolescence, or less commonly arise during that period. Primary osteoporosis is typically due to osteogenesis imperfecta or idiopathic juvenile osteoporosis. Secondary osteoporosis arises as a result of a variety of conditions, most of which fall under thematic headings...

ea0036P16 | (1) | BSPED2014

Leptin is associated with bone microstructural changes in obese children

Dimitri Paul , Paggiosi Margaret , King David , Bishop Nick , Eastell Richard

Background: Bone mass is low and fracture risk is higher in obese children. We wished to ascertain the relationships of obesity-related changes in hormones with skeletal microstructure.Method: Children aged 8–15 years matched by gender and pubertal stage were recruited into lean and obese groups (18 pairs). We used high resolution peripheral quantitative computed tomography (HRpQCT – resolution-82 μm) to assess three-dimensional cortical a...

ea0039ep13 | Bone | BSPED2015

Influence of skin colour, ethnicity, and genotype on the response to vitamin D treatment

Gopal Kothandapani Jaya Sujatha , Evans Lucy , Walsh Jennifer , Eastell Richard , Bishop Nick

Background: Over-dosing and under-dosing of vitamin D in children and young people appears to be common, based on our audit of current practice. The contribution of ethnicity, skin colour, and vitamin D binding protein (VDBP) genotype has not been fully explored during vitamin D treatment.Objective: To investigate how ethnicity/skin colour and genetic variation affect the response to 150 000 units of vitamin D administered to young adults of white Caucas...

ea0039ep14 | Bone | BSPED2015

Increase in lean mass may augment gains in bone mass and size in patients with osteogenesis imperfecta treated with bisphosphonates

Gopal Kothandapani Jaya Sujatha , Sritharan Shironisha , Jacques Richard , Bishop Nick , Dimitri Paul

Background: The role of bisphosphonates in improving bone mass in patients with osteogenesis impefercta (OI) is well established. However, the impact of bisphosphonate therapy on body composition in relation to increasing bone mass remains relatively unexplored.Methods: Change in DXA-derived subtotal body (TBLH) and lumbar spine (LS: L1–L4) bone mineral content (BMC (g)), bone area (BA (cm2)), areal bone mineral density (aBMD (g/cm2<...

ea0058p007 | Bone | BSPED2018

Impact of type 1 diabetes mellitus on skeletal integrity and strength assessed by HRpQCT

Devaraja Janani , Dimitri Paul , Jacques Richard , Paggiosi Margaret , Clark Carolyn , Bishop Nick

Introduction: Adults with Type 1 Diabetes Mellitus (T1DM) are at risk of premature osteoporosis and fractures. The onset of T1DM typically starts during childhood and adolescence thus the effects of diabetes on the skeleton may be established in this period. Studies in children primarily use DXA to evaluate the effects of T1DM on bone with conflicting results. We present the first study in children assessing the impact of T1DM on skeletal microstructure and strength, using HRp...

ea0095oc6.2 | Oral Communications 6 | BSPED2023

Children with hypophosphatasia treated with asfotase alfa: analysis from the UK Patients Cohort

Padidela Raja , Bishop Nick , Arundel Paul , Fang Shona , Zygouras Alexandros , Mughal Zulf , Shaw Nick , Saraff Vrinda

Objective: To describe outcomes among children with hypophosphatasia (HPP) receiving asfotase alfa.Methods: This prospective, real-world study used data from all children with HPP receiving asfotase alfa in the UK Managed Access Agreement (MAA) to assess functional, health-related quality-of-life, and safety outcomes. Visits occurred at MAA enrolment, 3 and 6 months after enrolment, and every 6 months thereafter. Assessm...